8-K: Entero Therapeutics Acquires GridAI, Pivots to AI Energy

Entero Therapeutics, Inc. has acquired 100% of GridAI Corp, a grid-edge AI platform, marking a strategic pivot into the high-growth AI energy-infrastructure market.

Summary

• Entero Therapeutics, Inc. (ENTO) acquired 100% of GridAI Corp, a Nevada corporation, on September 30, 2025.
• GridAI owns 75% of AMPX UK Holdings, a Cayman Islands company, and is expected to acquire an additional 24% of AMPX shares from AMP Solar Group Inc.
• The purchase price for GridAI consisted of 424,348 shares of ENTO common stock (representing 19.99% of outstanding common stock) and 38,801,546 shares of Series H Non-Voting Convertible Preferred Stock.
• The Series H Preferred Shares are convertible into an aggregate of 38,801,546 shares of common stock, subject to shareholder approval and the achievement of six specific milestone events related to AMPX's business.
• Upon full conversion, the former GridAI shareholders will own approximately 82.5% of ENTO's fully-diluted common stock, while existing ENTO shareholders will retain approximately 17.5%.
• The acquisition positions ENTO in the AI energy-infrastructure market, aiming to address the increasing power demand from data centers and integrate distributed energy resources.

Sentiment

Score: 8

Explanation: The acquisition represents a significant strategic pivot into a high-growth, high-demand sector (AI energy infrastructure) with substantial market tailwinds. While there are execution and integration risks, the potential for scalable recurring revenues and leveraging the public platform for growth is strong. The potential for significant dilution is a concern, but the strategic rationale is compelling.

Positives

• Strategic entry into the high-growth AI + energy nexus market, aligning with significant hyperscaler spending on data centers.
• GridAI's scalable software and services model targets recurring SaaS-like revenues from utilities and retailers.
• Leveraging ENTO's public-company platform is expected to accelerate GridAI's go-to-market strategy, partnerships, and project financing.
• Diversifies ENTO's portfolio into critical infrastructure software, opening new opportunities in energy flexibility, virtual power plants (VPPs), and transactive energy.
• The company believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement ($2.5 million) as a result of the Share Exchange.

Negatives

• Significant potential dilution for existing ENTO shareholders, as former GridAI shareholders will own approximately 82.5% of the fully-diluted common stock post-conversion.
• Conversion of Series H Preferred Stock is contingent on shareholder approval and the achievement of six specific business milestones, introducing execution risk.
• Failure to obtain shareholder approval for the conversion after three meetings could lead to rescission of the agreement and a $1,000,000 break fee payable by ENTO.
• The company's continued listing on Nasdaq is not assured until Nasdaq makes a final determination regarding compliance.
• Potential adjustment to the Series H Preferred Stock conversion ratio (from 1:1,000 to 1:1,483.93) if 11,911 common shares, 42,562 warrants, 2,737 options, and 11,777.418 Series G Preferred Stock are not cancelled by December 31, 2025.

Risks

• Nasdaq Delisting Risk: Entero Therapeutics previously received a notice of non-compliance with Nasdaq's minimum stockholders' equity requirement. While the company believes the Share Exchange has brought it into compliance, there are no assurances regarding continued listing, and delisting remains a possibility until Nasdaq's final determination.
• Shareholder Approval Risk: The conversion of the Series H Non-Voting Convertible Preferred Stock into common stock requires shareholder approval. Failure to secure this approval after up to three stockholder meetings could lead to the rescission of the Share Exchange Agreement and a $1,000,000 break fee payable by Entero Therapeutics.
• Milestone Achievement Risk: The automatic conversion of Series H Preferred Stock is tied to the achievement of six specific milestone events related to AMPX's business, introducing operational and execution risks.
• Dilution Risk: The issuance of a large number of common shares upon conversion of the Series H Preferred Stock (representing 82.5% of fully-diluted common stock) will significantly dilute existing shareholders.
• Financing Risk: Entero Therapeutics is required to complete a proposed financing of at least $3 million within 30 days of the closing, and maintain at least $2 million in available cash until then. Failure to secure this financing could impact operations.
• Integration Risk: Integrating GridAI's operations and technology into Entero Therapeutics, while continuing existing biopharmaceutical operations, presents integration challenges.
• Intellectual Property Risk: GridAI's use of AMPX Intellectual Property may involve payment of fees or royalties to third-party owners, and there's a risk that AMPX may not be able to use such IP without these payments.

Future Outlook

Entero Therapeutics intends to scale GridAI's solutions to help utilities and hyperscalers manage AI-driven power demand and improve grid reliability. The company will continue its prior biopharmaceutical operations alongside GridAI as a wholly-owned subsidiary, pursuing opportunities at the intersection of AI and energy infrastructure. The conversion of Series H Preferred Stock is tied to six specific business milestones for AMPX, indicating a focus on operational achievements post-acquisition. A proposed financing of at least $3 million is expected within 30 days of closing.

Management Comments

• "This transaction is transformative for ENTO."
• "By combining GRID AIs grid-edge intelligence with our public-company platform, we intend to scale solutions that help utilities and hyperscalers meet unprecedented AI-driven power demand while improving grid reliability for consumers and enterprises alike."

Industry Context

The acquisition positions Entero Therapeutics in the rapidly expanding AI energy-infrastructure market. AI workloads are projected to significantly increase electricity consumption from data centers, with Goldman Sachs Research forecasting a ~50% rise by 2027 and up to 165% by 2030. Hyperscaler capital expenditure is surging, with some analyses pointing to multi-trillion-dollar AI-related infrastructure spending by 2029, exemplified by a $14.2 billion agreement between CoreWeave and Meta. GridAI's platform directly addresses the urgent challenge faced by governments and network operators in managing localized loads from AI data centers and integrating variable renewables, by enabling automated demand shaping and distributed energy resource aggregation.

Comparison to Industry Standards

• Goldman Sachs Research projects global data-center power demand to rise approximately 50% by 2027 (to ~92 GW) and as much as 165% by 2030 versus 2023, driven by AI inference and training proliferation.
• Public estimates indicate hyperscaler capital expenditure is in the hundreds of billions annually, with some analyses suggesting cumulative AI-related infrastructure spending could surpass the multi-trillion-dollar mark by 2029.
• A specific example of this trend is the $14.2 billion multi-year AI infrastructure agreement between CoreWeave and Meta, highlighting sustained hyperscaler investment to secure GPU capacity and power-dense facilities.

Management Changes

Corporate Governance

Legal Proceedings

• No new specific legal proceedings are mentioned as pending or threatened against the company or GridAI/AMPX that would prevent the closing. The filing generally states that there are no actions pending or threatened that would have a Material Adverse Effect on the Company or AMPX, or challenge the transactions.

Related Party Transactions

• The Share Exchange itself involves the sellers of GridAI becoming significant shareholders and board members of Entero Therapeutics, which inherently creates a related party relationship post-closing.
• Equity incentives (restricted stock awards and options) are to be issued to GridAI/AMPX personnel, aligning their interests with the combined entity.

Stakeholder Impact

• Shareholders (Existing ENTO): Significant potential dilution (from 100% to 17.5% fully-diluted ownership) and a shift in board control. Potential for substantial upside if the AI energy strategy is successful, but also risks associated with Nasdaq listing and shareholder approval.
• Shareholders (Former GridAI): Become majority owners (82.5% fully-diluted) of a Nasdaq-listed company, gaining board control and liquidity potential through registration rights. Their investment is tied to the achievement of AMPX business milestones.
• Employees (GridAI/AMPX): Retention and alignment incentives through restricted stock awards (up to 2,000,000 shares) and stock options (up to 3,800,000 shares at $0.66/share), subject to shareholder approval.
• Customers/Suppliers (GridAI/AMPX): Potential for accelerated growth and expanded market reach due to ENTO's public-company platform and access to capital.
• Regulatory Authorities (Nasdaq): The company's continued listing is under review, and a final determination is pending.

Next Steps

• Hold a stockholder meeting as promptly as practicable to obtain approval for the conversion of Series H Preferred Shares and other related proposals.
• File a registration statement with the SEC covering the resale of all Registrable Securities within 15 days after the preparation of required financial statements for GridAI or AMPX.
• Use best efforts to cause the registration statement to be declared effective within 90 days of filing.
• Complete a proposed financing with gross proceeds of not less than $3 million no later than 30 days after the closing.
• Issue up to 2,000,000 restricted stock awards and grant options for up to 3,800,000 shares to GridAI/AMPX personnel, subject to shareholder approval.
• Amend the company's equity incentive plan to increase the number of shares available.
• GridAI/AMPX business to achieve six specific milestone events for the automatic conversion of Series H Preferred Stock.
• Nasdaq to make a final determination regarding the company's compliance with continued listing requirements.

Key Dates

Recommendation

The acquisition of GridAI represents a bold and strategically sound pivot for Entero Therapeutics into the high-growth AI energy infrastructure market, a sector experiencing unprecedented demand and investment. While the significant dilution for existing shareholders and the contingent nature of preferred share conversion (milestones, shareholder approval) introduce risks, the long-term potential for scalable, recurring revenues from GridAI's platform, coupled with the leverage of a public-company structure, positions the combined entity for substantial value creation. The move aligns with major industry trends and addresses critical infrastructure needs, making it a compelling opportunity for investors willing to accept the associated execution and integration challenges.

Keywords

AI energy infrastructure, GridAI, Entero Therapeutics, acquisition, distributed energy resources, Nasdaq listing, share exchange, Series H Preferred Stock, AMPX, data centers, AI workloads, demand shaping, virtual power plants, SaaS, corporate governance, stockholder approval, dilution, financing